Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4741 AL 4755

Stem cell therapy for Alzheimer's disease and related disorders: current status and future perspectives

Tong LM, Fong H, Huang Y.

Exp Mol Med. 2015 Mar 13;47(3):e151. doi: 10.1038/emm.2014.124.

β-sheet interfering molecules acting against β-amyloid aggregation and fibrillogenesis

Francioso A, Punzi P, Boffi A, Lori C, Martire S, Giordano C, D'Erme M, Mosca L.

Bioorg Med Chem. 2015 Apr 15;23(8):1671-83. doi: 10.1016/j.bmc.2015.02.041. Epub 2015 Feb 28.

First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study

Andreasen N, Simeoni M, Ostlund H, Lisjo PI, Fladby T, Loercher AE, Byrne GJ, Murray F, Scott-Stevens PT, Wallin A, Zhang YY, Bronge LH, Zetterberg H, Nordberg AK, Yeo AJ, Khan SA, Hilpert J, Mistry PC.

PLoS One. 2015 Mar 19;10(3):e0098153. doi: 10.1371/journal.pone.0098153. eCollection 2015.

Immunotherapeutic approaches for Alzheimer's disease

Wisniewski T, Goñi F.

Neuron. 2015 Mar 18;85(6):1162-76. doi: 10.1016/j.neuron.2014.12.064.

Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment

Li X, Song D, Leng SX.

Clin Interv Aging. 2015 Mar 10;10:549-60. doi: 10.2147/CIA.S74042. eCollection 2015.

Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease

Lauzon MA, Daviau A, Marcos B, Faucheux N.

J Control Release. 2015 May 28;206:187-205. doi: 10.1016/j.jconrel.2015.03.024. Epub 2015 Mar 22.

EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

Schmidt R, Hofer E, Bouwman FH, Buerger K, Cordonnier C, Fladby T, Galimberti D, Georges J, Heneka MT, Hort J, Laczó J, Molinuevo JL, O'Brien JT, Religa D, Scheltens P, Schott JM, Sorbi S.

Eur J Neurol. 2015 Jun;22(6):889-98. doi: 10.1111/ene.12707. Epub 2015 Mar 25.

Nonpharmacological therapy for the management of neuropsychiatric symptoms of Alzheimer's disease: linking evidence to practice

Staedtler AV, Nunez D.

Worldviews Evid Based Nurs. 2015 Apr;12(2):108-15. doi: 10.1111/wvn.12086. Epub 2015 Mar 21.

Oxidant/Antioxidant imbalance and the risk of Alzheimer's disease

Moneim AE.

Curr Alzheimer Res. 2015;12(4):335-49. doi: 10.2174/1567205012666150325182702.

Regulation of extracellular Zn(2+) homeostasis in the hippocampus as a therapeutic target for Alzheimer's disease

Takeda A, Tamano H.

Expert Opin Ther Targets. 2015;19(8):1051-8. doi: 10.1517/14728222.2015.1029454. Epub 2015 Mar 27.

Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials

Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E.

Dement Geriatr Cogn Disord. 2015;39(5-6):332-47. doi: 10.1159/000377672. Epub 2015 Mar 26.

The Human Alzheimer Disease Project: A New Call to Arms

Rosenberg RN, Petersen RC.

JAMA Neurol. 2015 Jun;72(6):626-8. doi: 10.1001/jamaneurol.2015.67.

Oral Chinese herbal medicine for kidney nourishment in Alzheimer's disease: a systematic review of the effect on MMSE index measures and safety

Zeng LF, Wang NS, Wang Q, Zou YP, Liang ZH, Kong LS, Wu HT, Liao NY, Liang XW, Mo YS.

Complement Ther Med. 2015 Apr;23(2):283-97. doi: 10.1016/j.ctim.2015.01.014. Epub 2015 Feb 13.

Advances in Alzheimer's disease drug development

Rafii MS, Aisen PS.

BMC Med. 2015 Mar 25;13:62. doi: 10.1186/s12916-015-0297-4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias